The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
High Resolution Genome-wide Genomic Analysis Of DCIS To Identify Genes Involved In Disease Initiation And Progression
Funder
National Health and Medical Research Council
Funding Amount
$543,370.00
Summary
DCIS is the most common type of noninvasive breast cancer and in some women may progress to malignant disease but little in know about how it develops. We will bring to bear our experience with cutting edge technology and access to extensive clinical resources to the analysis of a large series of pure DCIS with the aim of identifying previously unknown cancer causing genes. This data will lead to the identification of novel breast cancer genes that will assist clinical management.
MRNA Expression Profiling Of Chronic Lymphocytic Leukaemia (CLL) Cells From In Vivo Hypoxic Microenvironmental Niches; Applications For In Vitro Research And Clinical Management.
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
Chronic lymphocytic lymphoma (CLL) is the most frequently diagnosed leukaemia in adults and is still considered incurable. CLL cells proliferate in the lymph nodes and bone marrow; these are areas of the human body that are hypoxic when compared to blood. These hypoxic areas affect CLL cell survival, proliferation and treatment resistance. Changes that occur to CLL cells in these areas can be measured by gene expression profiling and modeled in a lab setting to identify targets for treatment.